For good reason, McMinnville residents love their street trees. Then there are tree streets. Where Quirk comes in is the ...

Later, St. Bernard praised the Virgin Mary as "the violet of humility, the lily of chastity, the rose of charity, the Balm of Gilead, and the golden gillyflower ... flower, shrub, and tree names that ...

Gilead’s short-term win could come at massive cost to the future of pharmaceutical innovation and to the health of the American public. The U.S. government filed the lawsuit in 2019, alleging ...

The company expects FDA approval this summer of its twice-a-year injectable HIV prevention drug lenacapavir. Gilead Sciences Inc.'s sales exceeded Wall Street expectations last year — thanks in ...

Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech ...

Outside of HIV, Gilead's oncology franchise ended the year in the growth category, as well. The company's cancer treatments pulled down $843 million in fourth-quarter sales, representing a 10% ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates.